Skip to Main Content
U.S. Department of Health & Human Services » National Institutes of Health
National Heart, Lung, and Blood Institute
Login | Register

Biologic Specimen and Data Repository Information Coordinating Center

  • Home (current)
  • About BioLINCC
    • About Us
    • FAQ
    • Contact Us
    • Glossary
  • Biospecimen and Data Resources
    • Overview
    • Studies
    • Teaching Datasets - Public Use Datasets
    • Renew Existing Data Use Agreement
    • Publications
    • Funding Opportunities
    • Non-BioLINCC Resources
    • Covid-19 Resources
  • Procedures and Forms
    • BioLINCC Handbook
    • Form Templates
    • Agreement Templates
  • Build/Submit New Collection
    • Informed Consent Considerations
    • NHLBI Biorepository Guide
    • Submit Datasets
    • Submit Biospecimens and Datasets
Home > Studies > Bypass Angioplasty Revascularization Investigation (BARI)

Bypass Angioplasty Revascularization Investigation (BARI)

Note that you will be prompted to log in or register an account

Accession Number
HLB00610707a

Study Type
Clinical Trial

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
1987-2004

NHLBI Division
DCVS

Dataset(s) Last Updated
July 17, 2020

Clinical Trial URLs
https://clinicaltrials.gov/ct/show/NCT00000462?order=3

Primary Publication URLs
N/A

Consent

Commercial Use Data Restrictions No

Data Restrictions Based On Area Of Research No

Available Data

The database contains a subset of the trial data and includes baseline characteristics and 10 year followup information on all 1,829 patients. Endpoints include subsequent revascularization, new myocardial infarction or death.

Objectives

The BARI (Bypass Angioplasty Revascularization Investigation) trial was designed to compare survival in patients randomized to receive either percutaneous transluminal coronary balloon angioplasty (PTCA) or coronary artery bypass grafting (CABG).

Background

Angioplasty and bypass surgery have been compared in numerous studies, but long-term clinical outcomes are limited. Symptomatic patients with multivessel coronary artery disease (n = 1,829) were randomly assigned to initial treatment with PTCA or CABG and followed up for an average of 10.4 years.

Conclusions

There was no significant long-term disadvantage regarding mortality or myocardial infarction associated with an initial strategy of PTCA compared with CABG. Among patients with treated diabetes, CABG conferred long-term survival benefit, whereas the 2 initial strategies were equivalent regarding survival for patients without diabetes.

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Study Datasets Only

Study Publications (6)

Study Documents

  • PDF Data Dictionary (PDF - 36.1 KB)
  • PDF Protocol (PDF - 5.4 MB)

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

  • About Us
  • FAQ
  • Glossary
  • Contact
  • Privacy Policy
  • Accessibility
  • FOIA
  • HHS Vulnerability Disclosure

  • U.S. Department of Health & Human Services
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • USA.gov
NIH… Turning Discovery Into Health®